pain in arm; felt tired; periods came too early; only 14 days after the previous ones; womb thickness was noticed to be too thick; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from a regulatory authority. the reporter is the patient. regulatory number: gb-mhra-webcovid-202202162053410040-uvd43. other case identifier(s): gb-mhra-adr 26611643. a female patient received bnt162b2 (comirnaty), administration date 06jan2022 (lot number: fn5254) as dose 3 (booster), single for covid-19 immunisation. relevant medical history included: "menopause" (unspecified if ongoing). concomitant medication(s) included: femoston taken for menopause. past drug history included: paracetamol. vaccination history included: bnt162b2 (first dose; lot number; et8885), administration date: 26may2021, for covid-19 immunisation, reaction(s): "periods were late approximately 3 weeks", "for several months, the periods were irregular, and the period cycle became longer", "for several months, the periods were irregular, and the period cycle became longer"; bnt162b2 (second dose; did not affect periods), administration date: jul2021, for covid-19 immunization. the following information was reported: pain in extremity (medically significant), outcome "unknown", described as "pain in arm"; fatigue (medically significant), outcome "unknown", described as "felt tired"; polymenorrhoea (medically significant), outcome "unknown", described as "periods came too early; only 14 days after the previous ones"; endometrial thickening (medically significant), outcome "not recovered", described as "womb thickness was noticed to be too thick". the events "pain in arm", "felt tired", "periods came too early; only 14 days after the previous ones" and "womb thickness was noticed to be too thick" were evaluated at the physician office visit. the patient underwent the following laboratory tests and procedures: sars-cov-2 test: negative, notes: no - negative covid-19 test; ultrasound scan: womb thickness increased, notes: womb thickness was noticed to be too thick. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. patient has not had symptoms associated with covid-19. no follow-up attempts are possible. no further information is expected

test name: covid-19 virus test; test result: negative ; comments: no - negative covid-19 test; test name: ultrasound; result unstructured data: test result:womb thickness increased; comments: womb thickness was noticed to be too thick

na

na